^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    thiotepa

    i
    Other names: DSP-1958
    Company:
    Generic mfg.
    Drug class:
    DNA synthesis inhibitor, Alkylating agent
    Related drugs:
    4d
    ASCT With TEAM Conditioning for Lymphoma With High Risk of CNS Relapse (clinicaltrials.gov)
    P2, N=45, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University
    New P2 trial
    |
    cytarabine • etoposide IV • melphalan • thiotepa
    4d
    IELSG32: Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma (clinicaltrials.gov)
    P2, N=227, Completed, International Extranodal Lymphoma Study Group (IELSG) | N=126 --> 227
    Enrollment change
    |
    Rituxan (rituximab) • cytarabine • carmustine • thiotepa • methotrexate IV
    13d
    NCI-2019-03188: Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS) (clinicaltrials.gov)
    P2, N=120, Recruiting, Fred Hutchinson Cancer Center | Trial completion date: Dec 2028 --> Dec 2029 | Trial primary completion date: Dec 2026 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    cyclophosphamide • sirolimus • fludarabine IV • thiotepa • busulfan • cyclosporin A microemulsion • methotrexate IV
    13d
    Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Thiotepa in Treating Patients With Non-malignant Disorders (clinicaltrials.gov)
    P2, N=40, Recruiting, Fred Hutchinson Cancer Center | Trial completion date: Jul 2027 --> Jul 2028 | Trial primary completion date: Jul 2027 --> Jul 2028
    Trial completion date • Trial primary completion date
    |
    CD33 (CD33 Molecule) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • CD34 (CD34 molecule) • HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    fludarabine IV • thiotepa • busulfan • Grafapex (treosulfan)
    14d
    RESOLVE trial: Registry and clinical trial comparing standard intensity and reduced intensity treatment in patients with AML or CLL who do not have residual disease. (2024-512503-39-00)
    P4, N=289, Recruiting, Medizinische Hochschule Hannover | N=128 --> 289
    Enrollment change • Minimal residual disease
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib) • cytarabine • Gazyva (obinutuzumab) • cyclophosphamide • etoposide IV • midostaurin • Vanflyta (quizartinib) • Mylotarg (gemtuzumab ozogamicin) • daunorubicin • idarubicin hydrochloride • mitoxantrone • cladribine • fludarabine IV • thiotepa • busulfan • Grafapex (treosulfan)
    15d
    CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma (clinicaltrials.gov)
    P1, N=60, Recruiting, St. Jude Children's Research Hospital | Not yet recruiting --> Recruiting | Trial completion date: Dec 2034 --> Dec 2035 | Trial primary completion date: Dec 2030 --> Dec 2031
    Enrollment open • Trial completion date • Trial primary completion date
    |
    cyclophosphamide • melphalan • fludarabine IV • mesna • thiotepa • Neupogen (filgrastim)
    17d
    RESOLVE trial: Registry and clinical trial comparing standard intensity and reduced intensity treatment in patients with AML or CLL who do not have residual disease. (2024-512503-39-00)
    P4, N=128, Recruiting, Medizinische Hochschule Hannover | N=52 --> 128
    Enrollment change • Minimal residual disease
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib) • cytarabine • Gazyva (obinutuzumab) • cyclophosphamide • etoposide IV • midostaurin • Vanflyta (quizartinib) • Mylotarg (gemtuzumab ozogamicin) • daunorubicin • idarubicin hydrochloride • mitoxantrone • cladribine • fludarabine IV • thiotepa • busulfan • Grafapex (treosulfan)
    20d
    HAP2HCT: TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies (clinicaltrials.gov)
    P2, N=69, Active, not recruiting, St. Jude Children's Research Hospital | N=140 --> 69 | Trial completion date: Aug 2025 --> Jun 2026
    Enrollment change • Trial completion date
    |
    FLT3 (Fms-related tyrosine kinase 3) • RUNX1 (RUNX Family Transcription Factor 1) • KMT2A (Lysine Methyltransferase 2A) • ETV6 (ETS Variant Transcription Factor 6) • WT1 (WT1 Transcription Factor) • CREBBP (CREB binding protein) • NUP98 (Nucleoporin 98 And 96 Precursor 2) • NSD1 (Nuclear Receptor Binding SET Domain Protein 1) • HOXA9 (Homeobox A9) • NUP214 (Nucleoporin 214) • CBFA2T3 (CBFA2/RUNX1 Partner Transcriptional Co-Repressor 3) • GLIS2 (GLIS Family Zinc Finger 2) • KAT6A (Lysine Acetyltransferase 6A) • KDM5A (Lysine Demethylase 5A) • DEK (DEK Proto-Oncogene) • AFDN (Afadin, Adherens Junction Formation Factor) • MLLT10 (MLLT10 Histone Lysine Methyltransferase DOT1L Cofactor)
    |
    FLT3-ITD mutation
    |
    cyclophosphamide • Blincyto (blinatumomab) • melphalan • fludarabine IV • mesna • thiotepa • Neupogen (filgrastim)
    22d
    CD34+ Transplants for Leukemia and Lymphoma (clinicaltrials.gov)
    P2, N=100, Not yet recruiting, Guenther Koehne | Trial completion date: Sep 2032 --> Jun 2033 | Trial primary completion date: Sep 2032 --> Jun 2033
    Trial completion date • Trial primary completion date
    |
    CD34 (CD34 molecule)
    |
    cyclophosphamide • melphalan • fludarabine IV • thiotepa • busulfan
    23d
    The Safety and Efficacy of the Regimen of Thiotepa + Fludarabine +Granulocyte Colony-Stimulating Factor+ Cytarabine + Busulfan in Single Unrelated Umbilical Cord Blood Transplantation (clinicaltrials.gov)
    P2, N=44, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New P2 trial
    |
    cytarabine • fludarabine IV • thiotepa • busulfan
    1m
    Immune Disorder HSCT Protocol (clinicaltrials.gov)
    P2, N=20, Active, not recruiting, Washington University School of Medicine | Recruiting --> Active, not recruiting | Trial completion date: Mar 2027 --> Apr 2026 | Trial primary completion date: Mar 2027 --> Apr 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Campath (alemtuzumab) • melphalan • fludarabine IV • thiotepa
    1m
    Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma (clinicaltrials.gov)
    P2, N=24, Recruiting, Zhejiang Cancer Hospital
    New P2 trial
    |
    Tyvyt (sintilimab) • Jaypirca (pirtobrutinib) • thiotepa